Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Neoadjuvant Chemo in ESCC
NCT04506138Phase 2Active, not recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2020
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhejiang Cancer Hospital. Started Aug 2020; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04506138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04506138.